Published by Josh White on 7th February 2022
(Sharecast News) - Drug discovery and development specialist ImmuPharma updated the market on the pharmacokinetic study of 'Lupuzor' on Monday, as part of the new, optimised international phase 3 trial of Lupuzor in lupus patients.
URL: http://www.digitallook.com/dl/news/story/32444998/...